BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38125769)

  • 1. Mutations in the DNA polymerase binding pathway affect the immune microenvironment of patients with small-cell lung cancer and enhance the efficacy of platinum-based chemotherapy.
    Lin A; Mou W; Zhu L; Yang T; Zhou C; Zhang J; Luo P
    Cancer Innov; 2023 Dec; 2(6):500-512. PubMed ID: 38125769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the TGF-
    Lin A; Zhu L; Jiang A; Mou W; Zhang J; Luo P
    Dis Markers; 2022; 2022():8766448. PubMed ID: 36590751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
    Chen JN; Feng T; Yang J; Li HM; Yuan P; Ma F; Yin LL; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):112-117. PubMed ID: 30862140
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemotherapy- and Immune-Related Gene Panel in Prognosis Prediction and Immune Microenvironment of SCLC.
    Chen MY; Zeng YC; Zhao XH
    Front Cell Dev Biol; 2022; 10():893490. PubMed ID: 35784467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. m
    Zhang Z; Zhang C; Luo Y; Wu P; Zhang G; Zeng Q; Wang L; Yang Z; Xue L; Zheng B; Zeng H; Tan F; Xue Q; Gao S; Sun N; He J
    BMC Med; 2021 Nov; 19(1):284. PubMed ID: 34802443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
    Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
    He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
    Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
    Wang Z; Zhao J; Ma Z; Cui J; Shu Y; Liu Z; Cheng Y; Leaw SJ; Wu Y; Ma Y; Tan W; Ma X; Zhang Y; Wang J
    Lung Cancer; 2020 Sep; 147():259-268. PubMed ID: 32769013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
    Lee GW; Go SI; Cho YJ; Jeong YY; Kim HC; Duk Lee J; Hwang YS; Ko GH; Lee JH; Kim DC; Yang JW; Oh S; Lee JS
    J Thorac Oncol; 2012 Mar; 7(3):528-34. PubMed ID: 22258474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study.
    Wang L; Lei X; Wang X
    Comput Math Methods Med; 2022; 2022():2848220. PubMed ID: 35586668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curative efficacy might be an early predictor of prognosis in patients with small cell lung cancer treated with 2 cycles of platinum-based first-line chemotherapy.
    Zhu K; Jiang M; Xu Y; Chen P; Wang H; Yu J; Zhu J; Zhao W; Meng D; He Y
    J Thorac Dis; 2021 Feb; 13(2):1205-1214. PubMed ID: 33717593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
    Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study).
    Li D; Huang Z; Zhong J; Lin L; Zhang G; Zhuang W; Liu Z
    BMC Cancer; 2023 Aug; 23(1):753. PubMed ID: 37580661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Subtypes and Tumor Microenvironment Characteristics of Small-Cell Lung Cancer Associated with Platinum-Resistance.
    Kim J; Kim S; Park SY; Lee GK; Lim KY; Kim JY; Hwang JA; Yu N; Kang EH; Hwang M; Song BR; Park C; Han JY
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
    Yi Y; Qiu Z; Yao Z; Lin A; Qin Y; Sha R; Wei T; Wang Y; Cheng Q; Zhang J; Luo P; Shen W
    Front Cell Dev Biol; 2021; 9():770811. PubMed ID: 35087829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study.
    Roussel-Simonin C; Gougis P; Lassoued D; Vozy A; Veyri M; Morardet L; Wassermann J; Foka Tichoue H; Jaffrelot L; Hassani L; Perrier A; Bergeret S; Taillade L; Spano JP; Campedel L; Abbar B
    Acta Oncol; 2023 Jun; 62(6):579-586. PubMed ID: 37276270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy.
    Wang C; Jin S; Xu S; Cao S
    Lung; 2020 Apr; 198(2):405-414. PubMed ID: 32016563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurbinectedin for the treatment of small cell lung cancer.
    Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
    Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.